search
Back to results

Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures

Primary Purpose

Atrial Fibrillation

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Esophageal warming device (Attune Medical, Chicago, IL
Sponsored by
Advanced Cooling Therapy, Inc., d/b/a Attune Medical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Atrial Fibrillation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult patients (age over 18 years).
  • Undergoing cryoablation for the treatment of atrial fibrillation, including pulmonary vein isolation.
  • Patients must be able to understand and critically review the informed consent form.
  • Subjects must understand and agree to study requirements and sign a written informed consent.

Exclusion Criteria:

  • Patients who are unable to provide informed consent.
  • Significant co-morbidities that preclude standard ablation procedure.
  • Patients with <40 kg of body mass.
  • Patients with relevant esophageal pathology (e.g. esophageal cancer).

Sites / Locations

  • Winchester Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Esophageal warming

Arm Description

Patients receive the Attune Medical Esophageal Heat Transfer Device

Outcomes

Primary Outcome Measures

Total Time of Active Ablation Procedure
Total time of active ablation procedure measured from trans-septal puncture to achievement of Pulmonary Vein Isolation (PVI)

Secondary Outcome Measures

Total Procedure Time
Total procedure time from patient entry to Electrophysiology (EP) lab until discharge to Post-Anesthesia Care Unit (PACU)
Number of Procedural Pauses During Left Atrial Instrumentation
Number of procedural pauses during left atrial instrumentation measured from trans-septal puncture to achievement of Pulmonary Vein Isolation (PVI)
Total Duration of Fluoroscopy Use
Total duration of fluoroscopy use during left atrial instrumentation measured from trans-septal puncture to achievement of Pulmonary Vein Isolation (PVI)

Full Information

First Posted
September 10, 2019
Last Updated
April 19, 2022
Sponsor
Advanced Cooling Therapy, Inc., d/b/a Attune Medical
Collaborators
Winchester Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04087122
Brief Title
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
Official Title
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
September 30, 2019 (Actual)
Primary Completion Date
July 30, 2020 (Actual)
Study Completion Date
December 31, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Advanced Cooling Therapy, Inc., d/b/a Attune Medical
Collaborators
Winchester Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Left atrial catheter ablation including pulmonary vein isolation is a standard therapy in the management of symptomatic atrial fibrillation; however thermal esophageal injury is a known potential consequence of this procedure. Delivery of radiofrequency (RF) energy necessary to perform left atrial ablation has the potential to cause injury to the nearby esophagus including ulceration, hematoma, spasm, esophageal motility disorders, and, in the most extreme case, atrial-esophageal fistula.Esophageal mucosal lesions are the likely precursor to AEF, and esophageal mucosal lesions have been detected on post-ablation endoscopy after pulmonary vein isolation with an incidence ranging from 3% to 60%. Active esophageal cooling during RF ablation as a means of esophageal injury prevention has been investigated through mathematical models, pre-clinical studies, and in clinical trials. Existing data support the efficacy of this approach, but the practice has not been widely adopted due to lack of a commercially available device. The aim of this study is to evaluate the impact on procedural efficiency of ablation procedures performed using esophageal heat transfer to warm the esophagus during left atrial cryoablation.
Detailed Description
This study is a prospective, pilot study using the Attune Medical ensoETM esophageal heat transfer device to actively warm the esophagus during cryoablation procedures. This design is appropriate to gather the data needed regarding overall procedural time, compare this to historical controls, and estimate a sample size for a larger study powered for statistical significance. Once patient consent is obtained, the subject will undergo preparation and anesthesia procedures following standard practice. Once the patient is intubated, the esophageal heat transfer device will be placed into the esophagus according to the IFU. The device will remain in place until the ablation procedure is completed and will be removed before extubation. Left atrial cryoablation using the standard approach will be performed with the ensoETM set at a temperature of 42 degrees C. All patients will be followed up in total for 6 weeks (Long Term FU visit) after the procedure to document any clinical complication related to thermal esophageal injuries if applicable.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Esophageal warming
Arm Type
Experimental
Arm Description
Patients receive the Attune Medical Esophageal Heat Transfer Device
Intervention Type
Device
Intervention Name(s)
Esophageal warming device (Attune Medical, Chicago, IL
Intervention Description
Prospective, single center pilot stud
Primary Outcome Measure Information:
Title
Total Time of Active Ablation Procedure
Description
Total time of active ablation procedure measured from trans-septal puncture to achievement of Pulmonary Vein Isolation (PVI)
Time Frame
Study Day 1 for all patients enrolled, during left atrial ablation procedures using cryoablation
Secondary Outcome Measure Information:
Title
Total Procedure Time
Description
Total procedure time from patient entry to Electrophysiology (EP) lab until discharge to Post-Anesthesia Care Unit (PACU)
Time Frame
Study Day 1 for all patients enrolled from patient entry to Electrophysiology (EP) lab until post procedure discharge to Post-Anesthesia Care Unit (PACU)]
Title
Number of Procedural Pauses During Left Atrial Instrumentation
Description
Number of procedural pauses during left atrial instrumentation measured from trans-septal puncture to achievement of Pulmonary Vein Isolation (PVI)
Time Frame
Study Day 1 for all patients, during left atrial ablation procedures using cryoablation
Title
Total Duration of Fluoroscopy Use
Description
Total duration of fluoroscopy use during left atrial instrumentation measured from trans-septal puncture to achievement of Pulmonary Vein Isolation (PVI)
Time Frame
Study Day 1 for all patients, during left atrial ablation procedures using cryoablation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patients (age over 18 years). Undergoing cryoablation for the treatment of atrial fibrillation, including pulmonary vein isolation. Patients must be able to understand and critically review the informed consent form. Subjects must understand and agree to study requirements and sign a written informed consent. Exclusion Criteria: Patients who are unable to provide informed consent. Significant co-morbidities that preclude standard ablation procedure. Patients with <40 kg of body mass. Patients with relevant esophageal pathology (e.g. esophageal cancer).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daniel Alexander, MD
Organizational Affiliation
Winchester Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Zachary Hollis, MD
Organizational Affiliation
Winchester Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Winchester Medical Center
City
Winchester
State/Province
Virginia
ZIP/Postal Code
22601
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures

We'll reach out to this number within 24 hrs